Hongmei Sun

CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study.

Baohui Han, Kai Li, Runxiang Yang, Yongzhong Luo et autres

LBA8502 Background: Anti-PD-(L) 1 monotherapy has been the standard first-line treatment for PD-L1 positive NSCLC, but its clinical benefit remains unsatisfactory. Benmelstobart (TQB2450) is a humanized monoclonal antibody against PD-L1 and anlotinib is a multikinase inhibitor that has been approved as the …

cn (code pays fourni par la source)

Single-cell RNA sequencing reveals potential therapeutic targets in the tumor microenvironment of lung squamous cell carcinoma

Junda Fan, Yu Chen, Yue Hong Gong, Hongmei Sun et autres

Lung squamous cell carcinoma (LUSC), accounting for 30% of lung cancer cases, lacks adequate research due to limited understanding of its molecular abnormalities. Our study analyzed public LUSC datasets to explore the tumor microenvironment (TME) composition using scRNA-seq from two cohorts. Applying …

cn (code pays fourni par la source)

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors

Mingchuan Zhao, Xichun Hu, Panpan Zhuang, Aiping Zeng et autres

Introduction: Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess the equivalence of LY01011 to denosumab in terms of efficacy and safety. Materials and methods: Eligible …

cn, vn (code pays fourni par la source)

Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study

Ying Cheng, Zhanyu Pan, Lin Wu, Bo Zhu et autres

cn (code pays fourni par la source)

440P Maximal tumor area as an independent prognostic factor: Enhancing prognostic assessment in resectable gastric adenocarcinoma

Jeannette Zhang, Y. Liu, Xintong Zhang, X. Wang et autres

cn (code pays fourni par la source)

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Caicun Zhou, Yanping Hu, Ekaterine Arkania, Saadettin Kılıçkap et autres

cn, ge, tr, us (code pays fourni par la source)

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

Rongrui Liu, Lianke Liu, Chuanhua Zhao, Yuxian Bai et autres

BACKGROUND: Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification …

cn (code pays fourni par la source)

Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study

Jianming Xu, Lianke Liu, Rongrui Liu, Yuxian Bai et autres

Abstract PurposeLarotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification …

cn, au (code pays fourni par la source)

Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement

Haiping Chen, Zhigang Gao, Shuang Bai, Xiaoqin Liu et autres

cn (code pays fourni par la source)

Up-regulation of CXCL8 expression is associated with a poor prognosis and enhances tumor cell malignant behaviors in liver cancer

Han Wang, Chundi Qin, Hongmei Sun, Yupeng Han

CXCL8, a member of CXC chemokines, was constitutively expressed in many types of human cancers, and its overexpression has been shown to play a critical role in promoting tumorigenesis. The purpose of the present study was to determine CXCL8 expression in a …

cn (code pays fourni par la source)

ALDH3B1 Is an Independent Prognostic Biomarker of Lung Adenocarcinoma

Hongmei Sun, Mingying Zhang, Li Li, Zongwen Huang

Background: Lung cancer is the leading cause of cancer-related death, and adenocarcinoma is the most common type of lung cancer. Although emerging evidence implicates the role of several aldehyde dehydrogenases in cancer progression, the expression and clinical significance of aldehyde dehydrogenase 3B1 …

us, cn (code pays fourni par la source)

CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties

Hongmei Sun, Jun Jia, Xiaoli Wang, Bo Ma et autres

cn, Éthiopie (code pays fourni par la source)